PE20100260A1 - Formas solidas del (2s, 3r, 4r, 5s, 6r)-2-(4-cloro-3-(4-etoxibenzil)fenil)-6-(metiltio) tetrahidro-2h-pirano-3,4,5-triol - Google Patents
Formas solidas del (2s, 3r, 4r, 5s, 6r)-2-(4-cloro-3-(4-etoxibenzil)fenil)-6-(metiltio) tetrahidro-2h-pirano-3,4,5-triolInfo
- Publication number
- PE20100260A1 PE20100260A1 PE2009000944A PE2009000944A PE20100260A1 PE 20100260 A1 PE20100260 A1 PE 20100260A1 PE 2009000944 A PE2009000944 A PE 2009000944A PE 2009000944 A PE2009000944 A PE 2009000944A PE 20100260 A1 PE20100260 A1 PE 20100260A1
- Authority
- PE
- Peru
- Prior art keywords
- methylthi
- pyrane
- ethoxybenzyl
- triol
- tetrahydro
- Prior art date
Links
- -1 4-CHLORO-3- (4-ETHOXYBENZYL) PHENYL Chemical class 0.000 title abstract 2
- 239000007787 solid Substances 0.000 title abstract 2
- QXAMTEJJAZOINB-UHFFFAOYSA-N oxane-3,4,5-triol Chemical compound OC1COCC(O)C1O QXAMTEJJAZOINB-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 238000002441 X-ray diffraction Methods 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
- C07H5/08—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to sulfur, selenium or tellurium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/14—Acyclic radicals, not substituted by cyclic structures attached to a sulfur, selenium or tellurium atom of a saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/04—Carbocyclic radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Crystallography & Structural Chemistry (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8142308P | 2008-07-17 | 2008-07-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20100260A1 true PE20100260A1 (es) | 2010-04-16 |
Family
ID=41137707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2009000944A PE20100260A1 (es) | 2008-07-17 | 2009-07-15 | Formas solidas del (2s, 3r, 4r, 5s, 6r)-2-(4-cloro-3-(4-etoxibenzil)fenil)-6-(metiltio) tetrahidro-2h-pirano-3,4,5-triol |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US8217156B2 (enExample) |
| EP (1) | EP2332947B1 (enExample) |
| JP (2) | JP2011528366A (enExample) |
| KR (2) | KR20170010069A (enExample) |
| CN (2) | CN107629097A (enExample) |
| AR (1) | AR072807A1 (enExample) |
| AU (1) | AU2009270973B2 (enExample) |
| CA (1) | CA2730931A1 (enExample) |
| CL (1) | CL2009001595A1 (enExample) |
| CO (1) | CO6351797A2 (enExample) |
| DK (1) | DK2332947T3 (enExample) |
| ES (1) | ES2656357T3 (enExample) |
| HK (1) | HK1243713A1 (enExample) |
| HU (1) | HUE035400T2 (enExample) |
| IL (1) | IL210269A (enExample) |
| MX (1) | MX2011000503A (enExample) |
| NO (1) | NO2332947T3 (enExample) |
| NZ (1) | NZ590184A (enExample) |
| PE (1) | PE20100260A1 (enExample) |
| PL (1) | PL2332947T3 (enExample) |
| PT (1) | PT2332947T (enExample) |
| RU (1) | RU2505543C2 (enExample) |
| SG (1) | SG185317A1 (enExample) |
| TW (1) | TWI472521B (enExample) |
| UA (1) | UA106048C2 (enExample) |
| UY (1) | UY31992A (enExample) |
| WO (1) | WO2010009197A1 (enExample) |
| ZA (1) | ZA201100175B (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI499414B (zh) * | 2006-09-29 | 2015-09-11 | Lexicon Pharmaceuticals Inc | 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法 |
| EP2183263B1 (en) | 2007-07-26 | 2011-10-26 | Lexicon Pharmaceuticals, Inc. | Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors |
| CN102149280B (zh) | 2008-07-15 | 2017-05-24 | 泰拉科斯有限公司 | 氘化苄基苯衍生物及其使用方法 |
| TWI472521B (zh) | 2008-07-17 | 2015-02-11 | Lexicon Pharmaceuticals Inc | （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）－２－（４－氯－３－（４－乙氧苄基）苯基）－６－（甲硫）四氫－２ｈ－哌喃－３，４，５－三醇的固體形態與其使用方法 |
| TWI562775B (en) * | 2010-03-02 | 2016-12-21 | Lexicon Pharmaceuticals Inc | Methods of using inhibitors of sodium-glucose cotransporters 1 and 2 |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| CN102453026A (zh) | 2010-10-27 | 2012-05-16 | 上海艾力斯医药科技有限公司 | C-芳基葡糖苷衍生物、制备方法及其应用 |
| TWI631963B (zh) * | 2011-01-05 | 2018-08-11 | 雷西肯製藥股份有限公司 | 包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法 |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| UA117574C2 (uk) * | 2012-11-20 | 2018-08-27 | Лексікон Фармасьютікалз, Інк. | Інгібітори котранспортера натрій-глюкози 1 |
| US20160272645A1 (en) | 2013-10-18 | 2016-09-22 | Medivation Technologies, Inc. | Heterocyclic Compounds and Methods of Use |
| CA2922058A1 (en) | 2013-10-18 | 2015-04-23 | Medivation Technologies, Inc. | Heterocyclic compounds and methods of use |
| CN108026133B (zh) | 2015-07-30 | 2021-05-07 | 公益财团法人微生物化学研究会 | 有效对抗多药耐药细菌的新的氨基糖苷抗生素 |
| WO2017202351A1 (zh) * | 2016-05-25 | 2017-11-30 | 苏州科睿思制药有限公司 | 一种钠-葡萄糖协同转运蛋白抑制剂药物的新晶型及其制备方法和用途 |
| WO2018067805A1 (en) | 2016-10-06 | 2018-04-12 | Teva Pharmaceutical Industries Ltd. | Solid state forms of sotagliflozin |
| EP3528800A1 (en) | 2016-10-19 | 2019-08-28 | Boehringer Ingelheim International GmbH | Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof |
| AU2019254371A1 (en) | 2018-04-17 | 2020-10-08 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CN110818722B (zh) * | 2018-08-14 | 2022-12-02 | 苏州鹏旭医药科技有限公司 | 三种化合物及其制备方法和在合成索格列净中的用途 |
| CN112218877B (zh) | 2018-08-27 | 2025-07-25 | 瑞泽恩制药公司 | 拉曼光谱在下游纯化中的应用 |
| KR20210065974A (ko) * | 2018-09-26 | 2021-06-04 | 렉시컨 파마슈티컬스 인코퍼레이티드 | N-(1-((2-(디메틸아미노)에틸)아미노)-2-메틸-1-옥소프로판-2-일)-4-(4-(2-메틸-5-((2s,3r,4r,5s,6r)-3,4,5-트리히드록시-6-(메틸티오)테트라히드로-2h-피란-2-일)벤질)페닐)부탄아미드의 결정질 형태 및 그의 합성 방법 |
| CN112955214B (zh) | 2018-10-29 | 2024-05-07 | 勃林格殷格翰国际有限公司 | 吡啶基磺酰胺衍生物、药物组合物及其用途 |
| CN112955215B (zh) | 2018-10-29 | 2024-05-17 | 勃林格殷格翰国际有限公司 | 吡啶基磺酰胺衍生物、药物组合物及其用途 |
| CN109824687B (zh) * | 2019-03-26 | 2022-03-22 | 上海凌凯医药科技有限公司 | 呋喃木糖衍生物的新合成方法 |
| CN113993865B (zh) * | 2019-07-05 | 2023-09-22 | 山东丹红制药有限公司 | 一种SGLTs抑制剂的晶型及其应用 |
| EP3771718A1 (en) | 2019-08-01 | 2021-02-03 | Lexicon Pharmaceuticals, Inc. | Process for preparing the crystalline form ii of sotagliflozin |
| EP3771480A1 (en) | 2019-08-01 | 2021-02-03 | Lexicon Pharmaceuticals, Inc. | Continuous process for preparing the crystalline form ii of sotagliflozin |
| WO2022144465A1 (en) | 2021-01-04 | 2022-07-07 | Charité-Universitätsmedizin Berlin | Sotagliflozin for improving left atrial function |
| US20220370485A1 (en) | 2021-01-14 | 2022-11-24 | Lexicon Pharmaceuticals, Inc. | Compounds and methods for treating or preventing cardiovascular diseases and conditions |
| CN113880701A (zh) * | 2021-10-10 | 2022-01-04 | 浙江司太立制药股份有限公司 | 一种抗糖尿病药物中间体及其制备方法 |
| US20250108032A1 (en) | 2023-09-28 | 2025-04-03 | Lexicon Pharmaceuticals, Inc. | Methods of treating type 1 diabetes and kidney disease |
| US20250114323A1 (en) | 2023-10-06 | 2025-04-10 | Lexicon Pharmaceuticals, Inc. | Methods of reducing the risk of cardiovascular events in patients with left ventricular hypertrophy |
| PL446852A1 (pl) * | 2023-11-27 | 2025-06-02 | Politechnika Rzeszowska im. Ignacego Łukasiewicza | Układ doprowadzający wodę do pralki |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3870699A (en) * | 1973-03-06 | 1975-03-11 | Upjohn Co | Lincomycin analogs |
| NZ519984A (en) * | 2000-01-07 | 2004-03-26 | Transform Pharmaceuticals Inc | High-throughput formation, identification, and analysis of diverse solid-forms |
| WO2006018150A1 (de) | 2004-08-11 | 2006-02-23 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| ATE445608T1 (de) | 2005-02-23 | 2009-10-15 | Boehringer Ingelheim Int | Glucopyranosylsubstituierte ((hetero)arylethynyl- benzyl)-benzenderivative und deren verwendung als inhibitoren des natriumabhängigen glucose- cotransporters typ 2 (sglt2) |
| CN1820858A (zh) * | 2006-03-10 | 2006-08-23 | 广西中医学院制药厂 | 多相物料喷雾方法及装置 |
| TWI499414B (zh) | 2006-09-29 | 2015-09-11 | Lexicon Pharmaceuticals Inc | 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法 |
| WO2008109591A1 (en) * | 2007-03-08 | 2008-09-12 | Lexicon Pharmaceuticals, Inc. | Phlorizin analogs as inhibitors of sodium glucose co-transporter 2 |
| EP2183263B1 (en) * | 2007-07-26 | 2011-10-26 | Lexicon Pharmaceuticals, Inc. | Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors |
| TWI472521B (zh) | 2008-07-17 | 2015-02-11 | Lexicon Pharmaceuticals Inc | （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）－２－（４－氯－３－（４－乙氧苄基）苯基）－６－（甲硫）四氫－２ｈ－哌喃－３，４，５－三醇的固體形態與其使用方法 |
-
2009
- 2009-07-01 TW TW98122274A patent/TWI472521B/zh active
- 2009-07-15 KR KR1020177001061A patent/KR20170010069A/ko not_active Ceased
- 2009-07-15 US US12/503,225 patent/US8217156B2/en active Active
- 2009-07-15 MX MX2011000503A patent/MX2011000503A/es active IP Right Grant
- 2009-07-15 CN CN201710477527.7A patent/CN107629097A/zh not_active Withdrawn
- 2009-07-15 NZ NZ590184A patent/NZ590184A/xx unknown
- 2009-07-15 HU HUE11155100A patent/HUE035400T2/en unknown
- 2009-07-15 RU RU2011105797/04A patent/RU2505543C2/ru active
- 2009-07-15 EP EP11155100.8A patent/EP2332947B1/en active Active
- 2009-07-15 JP JP2011518868A patent/JP2011528366A/ja active Pending
- 2009-07-15 DK DK11155100.8T patent/DK2332947T3/da active
- 2009-07-15 AR ARP090102685A patent/AR072807A1/es unknown
- 2009-07-15 CA CA2730931A patent/CA2730931A1/en not_active Abandoned
- 2009-07-15 KR KR1020117001024A patent/KR101707246B1/ko active Active
- 2009-07-15 PE PE2009000944A patent/PE20100260A1/es not_active Application Discontinuation
- 2009-07-15 SG SG2012077681A patent/SG185317A1/en unknown
- 2009-07-15 WO PCT/US2009/050636 patent/WO2010009197A1/en not_active Ceased
- 2009-07-15 CL CL2009001595A patent/CL2009001595A1/es unknown
- 2009-07-15 NO NO11155100A patent/NO2332947T3/no unknown
- 2009-07-15 AU AU2009270973A patent/AU2009270973B2/en active Active
- 2009-07-15 PL PL11155100T patent/PL2332947T3/pl unknown
- 2009-07-15 PT PT111551008T patent/PT2332947T/pt unknown
- 2009-07-15 UA UAA201101832A patent/UA106048C2/uk unknown
- 2009-07-15 CN CN2009801279245A patent/CN102112483A/zh active Pending
- 2009-07-15 ES ES11155100.8T patent/ES2656357T3/es active Active
- 2009-07-16 UY UY0001031992A patent/UY31992A/es not_active Application Discontinuation
-
2010
- 2010-12-26 IL IL210269A patent/IL210269A/en active IP Right Grant
-
2011
- 2011-01-06 ZA ZA2011/00175A patent/ZA201100175B/en unknown
- 2011-02-09 CO CO11014849A patent/CO6351797A2/es not_active Application Discontinuation
-
2012
- 2012-06-22 US US13/530,645 patent/US9067962B2/en active Active
-
2015
- 2015-09-30 JP JP2015193990A patent/JP6283337B2/ja active Active
-
2018
- 2018-03-02 HK HK18103068.1A patent/HK1243713A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20100260A1 (es) | Formas solidas del (2s, 3r, 4r, 5s, 6r)-2-(4-cloro-3-(4-etoxibenzil)fenil)-6-(metiltio) tetrahidro-2h-pirano-3,4,5-triol | |
| CL2011001757A1 (es) | Uso de una composicion farmaceutica que comprende un inhibidor de sglt2 (1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofuran-3-iloxi)-bencil]-benceno, para mejorar el control glucemico. | |
| PE20140983A1 (es) | Formas solidas de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona, y sus composiciones farmaceuticas y sus usos | |
| WO2015028969A3 (en) | Transduction buffer | |
| CL2015002145A1 (es) | Preparación, usos y formas sólidas de ácido obeticólico (divisional de solicitud n° 3475-2014) | |
| BR112015001101A2 (pt) | formas cristalinas de um inibidor de prolil hidroxilase | |
| MX374694B (es) | USO DE 1-CLORO-4-(ß-D-GLUCOPIRANOS-1-IL)-2-[4-((S)-TETRAHIDROFURAN-3-ILOXI)-BENCIL]-BENCENO EN COMBINACIÓN CON INSULINA PARA REDUCIR LA DOSIS DE INSULINA Y PARA MEJORAR EL CONTROL GLUCÉMICO EN PACIENTES CON DIABETES MELLITUS. | |
| CO6640246A2 (es) | Forma cristalina del inhibidor sglt2 bencilbenceno | |
| CL2008000403A1 (es) | Compuestos derivados de pentafluorotiobenzamido-acetonitrilo; composicion farmaceutica; y uso para tratar una infestacion por parasitos. | |
| CL2007003713A1 (es) | Compuestos derivados de 2-amino-4-oxo-3,5-dihidroimidazol; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar o prevenir una patologia relacionada con abeta, tales como alzheimer, parkinson, sindrome de down, entre otras | |
| HUE041364T2 (hu) | (2S,3R,4R,5S,6R)-2-(4-klór-3-(4-etoxibenzil)fenil)-6- (metiltio)tetrahidro-2H-pirán-3,4,5-triolt tartalmazó készítmények | |
| PH12018500071B1 (en) | Plinabulin compositions | |
| BRPI1009783A2 (pt) | compostos para o tratamento de distúrbios metabólicos. | |
| EA201200484A1 (ru) | Фармацевтическая композиция с действующими веществами - метформином и ситаглиптином или вилдаглиптином | |
| PE20131371A1 (es) | Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con este | |
| EA201600442A1 (ru) | Мягкая фармацевтическая композиция на водной основе, содержащая тапентадол | |
| CL2013000735A1 (es) | Uso de una composicion que comprende compuestos derivados de 1-h-imidazol-4-il sustituido para el tratamiento de enfermedades y condiciones de la piel, tales como rosacea, daño solar cronico, psoriasis, entre otras; kit farmaceutico. | |
| CL2014001861A1 (es) | Compuestos derivados de bencil sulfonamida, inhibidores de mogat-2; compuesto cristalino; composicion farmaceutica; y su uso en el tratamiento de la hipertrigliceridemia. | |
| CL2013001221A1 (es) | Compuesto clorhidrato de (4a-r, 9a-s)-1-(1h-benzoimidazol-5-carbonil-2,3,4,4a,9,9a-hexahidro-1 h-inden[2,1-b] piridin-6-carbonitrilo y sus formas cristalinas i y ii, inhibidores de hsd 1; composicion farmaceutica; metodo para producir la forma cristalina i del compuesto; metodo para producir la forma cristalina ii del compuesto. | |
| CL2008002045A1 (es) | Forma cristalina b de 3-(difluorometil)-1-metil-n-(3',4',5'triofluoro (1,1'-bifenil)-2-il)-h-pirazol-4-carboxamida; procedimiento de preparación de dicha forma cristalina; agente fitoprotector que la contiene y método para combatir el crecimiento de plantas no deseadas. | |
| CL2008000110A1 (es) | Uso de compuestos derivados de piranona sustituidos para el tratamiento del sindrome metabolico; y compuestos derivados de piranona sustituidos. | |
| PE20141528A1 (es) | Composicion fungicida agricola u horticola y procedimiento para controlar patogeno de plantas | |
| CL2014000895A1 (es) | Compuestos derivados de {2-cloro-4-[hidroxi(cicloalquil/heterociclil)]amino]fenil}acetonitrilo, moduladores selectivos del receptor androgeno; composicion farmaceutica; composicion farmceutica que comprende una forma cristalina; y su uso en el tratamiento de la atrofia muscular | |
| CL2013001054A1 (es) | Compuestos derivados de cianopirazoles, moduladores de la actividad del receptor gpr119 acoplado a la proteina g; composicion farmaceutica; y metodo para tratar una enfermedad, afeccion, o trastorno metabolico seleccionado de hiperlipidemia, diabetes tipo i, diabetes mellitus tipo ii, diabetes tipo i idiopatica, entre otras. | |
| CL2011001829A1 (es) | 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |